Nefrologia: eficácia dos inibidores da sglt2 na proteção renal em pacientes com doença renal crônica e diabetes tipo 2
DOI:
https://doi.org/10.18378/rebes.v14i3.10840Resumo
Este estudo aborda a eficácia dos inibidores do cotransportador sódio-glicose tipo 2 (SGLT2) na proteção renal em pacientes com diabetes mellitus tipo 2, enfatizando seu impacto na redução da progressão da doença renal crônica (DRC). Diante da crescente prevalência de diabetes tipo 2 e suas complicações renais, o problema investigado consiste na necessidade de compreender como os inibidores da SGLT2 podem contribuir para a proteção renal, além de fornecer controle glicêmico, comparando-os com outras terapias antidiabéticas. Dessa forma, o objetivo foi analisar as evidências clínicas disponíveis para avaliar a eficácia desses medicamentos na preservação da função renal e na redução de desfechos adversos associados à DRC em pacientes diabéticos. A metodologia utilizada baseou-se em uma revisão de literatura, com seleção de estudos publicados em bases de dados como PubMed, Scopus e Web of Science, utilizando palavras-chave específicas e aplicando critérios de inclusão e exclusão para garantir a relevância e qualidade das evidências analisadas. Os resultados obtidos indicaram que os inibidores da SGLT2 contribuem na proteção renal, demonstrando uma redução na progressão da DRC, além de benefícios adicionais, como a diminuição da albuminúria e a melhora da hemodinâmica renal. Comparados a outras terapias antidiabéticas, esses medicamentos mostraram superioridade na preservação da função renal, oferecendo também um perfil de segurança favorável, com efeitos colaterais manejáveis. Assim, concluiu-se que os inibidores da SGLT2 são uma abordagem terapêutica efetiva e segura, destacando-se como uma opção no manejo integrado do diabetes tipo 2, com implicações positivas para a qualidade de vida dos pacientes e a redução de complicações renais e cardiovasculares.
Downloads
Referências
DEFRONZO, Ralph A.; REEVES, W. Brian; AWAD, Alaa S. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nature Reviews Nephrology, v. 17, n. 5, p. 319-334, 2021.
EBELT, H. et al. Euglycemic ketoacidosis in patients with type 1 diabetes treated with SGLT2 inhibitors: A case series and review of the literature. Diabetes Care, v. 38, n. 9, p. 1687-1693, 2015.
GARCIA-ROPERO, Alvaro; BADIMON, Juan J.; SANTOS-GALLEGO, Carlos G. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert opinion on drug metabolism & toxicology, v. 14, n. 12, p. 1287-1302, 2018.
GOHDA, Tomohito; MURAKOSHI, Maki. Sodium-glucose cotransporter-2 inhibitors—miracle drugs for the treatment of chronic Kidney disease irrespective of the diabetes status: Lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials. International Journal of Molecular Sciences, v. 23, n. 22, p. 13749, 2022.
GOMEZ-PERALTA, Fernando et al. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Therapy, v. 8, p. 953-962, 2017.
HEERSPIKE, Erik R. et al. Pharmacologic management of chronic kidney disease in type 2 diabetes. BMJ, v. 363, p. k4267, 2018.
INGELFINGER, Julie R.; ROSEN, Clifford J. Clinical credence—SGLT2 inhibitors, diabetes, and chronic kidney disease. N Engl J Med, v. 380, n. 24, p. 2371-2373, 2019.
KATZ, Pamela M.; LEITER, Lawrence A. The role of the kidney and SGLT2 inhibitors in type 2 diabetes. Canadian Journal of Diabetes, v. 39, p. S167-S175, 2015.
KELLY, Michael S. et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgraduate medicine, v. 131, n. 1, p. 31-42, 2019.
LUPSA, Beatrice C.; INZUCCHI, Silvio E. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia, v. 61, n. 10, p. 2118-2125, 2018.
MCGUIRE, Darren K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA cardiology, v. 6, n. 2, p. 148-158, 2021.
MINZE, Molly G. et al. Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes. Current Diabetes Reviews, v. 14, n. 6, p. 509-517, 2018.
MONICA REDDY, R. P.; INZUCCHI, Silvio E. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine, v. 53, p. 364-372, 2016.
NEAL, Bruce et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, v. 377, n. 7, p. 644-657, 2017.
NEUEN, Brendon L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. The lancet Diabetes & endocrinology, v. 7, n. 11, p. 845-854, 2019.
NEVOLA, Riccardo et al. Cardiorenal impact of SGLT-2 inhibitors: A conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. Reviews in Cardiovascular Medicine, v. 23, n. 3, p. 106, 2022.
PAPAZAFIROU, O. et al. Incidence of genitourinary infections in patients with type 2 diabetes receiving SGLT2 inhibitors: A systematic review and meta-analysis. Diabetes Therapy, v. 12, p. 2855-2866, 2021.
PERKINS, Brent A. et al. CREDENCE trial: Canagliflozin to improve renal outcomes in type 2 diabetes and nephropathy. Journal of Clinical Medicine, v. 8, n. 7, p. 1133, 2019.
PUGLIESE, Giuseppe et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutrition, Metabolism and Cardiovascular Diseases, v. 29, n. 11, p. 1127-1150, 2019.
SAISHO, Yoshifumi. SGLT2 inhibitors: the star in the treatment of type 2 diabetes?. Diseases, v. 8, n. 2, p. 14, 2020.
SANTOS, Denise Francisca et al. Eficácia e segurança dos inibidores de SGLT2 na população pediátrica com Doença Renal Crônica. Journal of Medical and Biosciences Research, v. 1, n. 3, p. 148-159, 2024.
SCHEEN, André J. An update on the safety of SGLT2 inhibitors. Expert opinion on drug safety, v. 18, n. 4, p. 295-311, 2019.
SCHEEN, André J. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs, v. 75, p. 33-59, 2015.
SCHEEN, Andre J. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert opinion on drug safety, v. 14, n. 12, p. 1879-1904, 2015.
TOYAMA, Tadashi et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, v. 21, n. 5, p. 1237-1250, 2019.
VALLON, Volker. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annual review of medicine, v. 66, n. 1, p. 255-270, 2015.
VAN BAAR, Michael JB et al. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes care, v. 41, n. 8, p. 1543-1556, 2018.
WANNER, Christoph et al. Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine, v. 375, n. 4, p. 323-334, 2016.
WANNER, Christoph. EMPA-REG OUTCOME: the nephrologist's point of view. The American journal of cardiology, v. 120, n. 1, p. S59-S67, 2017.
WILDING, John et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Therapy, v. 9, p. 1757-1773, 2018.
ZELNIKER, Thomas A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, v. 393, n. 10166, p. 31-39, 2019.
ZINMAN, Bernard et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, v. 373, n. 22, p. 2117-2128, 2015.
ZOU, Cai-Yan et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Medicine, v. 98, n. 49, p. e18245, 2019.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Giulia Alves Filippozzi Rocha , Pedro Souto Borges , Camila Sousa Bragunce Alves , Lorena Ferreira Santos , Marcus Vinícius Leite Batista Lacerda , Brida Magalhães Teixeira Macedo , Giselle Cândida Pires Silva , Matheus Olímpio Batista Cavalcante
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Termo de cess